This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

38/100

✓ Peer-reviewed alzhub usefulness score 38 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Early diagnosis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) with mild dementia is becoming increasingly important to enable patients to receive appropriate treatment with available amyloid-targeting therapies. Reviews of AD prevalence and diagnostic and treatment patterns typically focus on global or western populations, but the situation in Asia, Australasia, and Pacific Nations (AAPN) countries is less clear. We performed a narrative review of literature for AD in several AAPN countries, focusing on patients with MCI or mild dementia who may benefit from early treatment. Published information regarding AD incidence and prevalence and current practice in AAPN countries is limited and the nature of available information differs between countries. However, AAPN countries include some of the most rapidly aging populations and show the associated increasing trend of all-cause dementia prevalence observed globally. Although lecanemab and donanemab are now approved for AD with MCI and mild dementia in several AAPN countries, the most appropriate diagnostic pathway for patients with MCI and early AD is not established. Even though the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment. Guidelines and national policies also need updating to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hsu, J., Park, K. H., Panegyres, P. K., Huang, Y. H., Eom, Y. I., Prusty, V., et al. (2025). Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries. The Journal of Prevention of Alzheimer s Disease. https://doi.org/10.1016/j.tjpad.2025.100362

Vancouver

Hsu J, Park KH, Panegyres PK, Huang YH, Eom YI, Prusty V, et al. Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries. The Journal of Prevention of Alzheimer s Disease. 2025. doi:10.1016/j.tjpad.2025.100362. PMID: 40887393.

BibTeX

@article{hsu2025-40887393,
  author  = {Hsu, Jung‐Lung and Park, Kee Hyung and Panegyres, Peter K. and Huang, Yao Hsien and Eom, Young In and Prusty, Vinay and Tan, Lolita Stephanie and Shea, Yat Fung},
  title   = {{Early Alzheimer’s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries}},
  journal = {The Journal of Prevention of Alzheimer s Disease},
  year    = {2025},
  doi     = {10.1016/j.tjpad.2025.100362},
  pmid    = {40887393},
  url     = {https://doi.org/10.1016/j.tjpad.2025.100362}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Published information regarding AD incidence and prevalence and current practice in AAPN countries is limited and the nature of available information differs between countries.
However, AAPN countries include some of the most rapidly aging populations and show the associated increasing trend of all-cause dementia prevalence observed globally.
Although lecanemab and donanemab are now approved for AD with MCI and mild dementia in several AAPN countries, the most appropriate diagnostic pathway for patients with MCI and early AD is not established.
Even though the AAPN region includes countries with routine access to advanced technologies, concerns have already been raised about the ability of healthcare systems in Australia, New Zealand, and Korea to respond to approvals of new AD therapies, including the need to ensure availability of biomarker testing and dementia specialists to allow patients to receive the early diagnosis required to enable appropriate treatment.
Guidelines and national policies also need updating to differentiate between dementia subtypes and include amyloid-targeting therapies for eligible patients with early AD.

Why it matters

This review found limited and inconsistent information on early Alzheimer's disease prevalence, diagnosis, and treatment in Asia, Australasia, and Pacific nations, despite rapidly aging populations. Although new amyloid-targeting therapies are approved in some countries, the best diagnostic pathway is not established and healthcare systems may struggle to respond.

New to this subject? Start with our plain-English guide: Alzheimer's in numbers →

Study details

Study designnarrative review
Evidence strengthLow

How this study scored 38/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer s Disease)
Journal's citation record	0 / 4	The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 8 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.7 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 5.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Yat Fung Shea: h-index 19 (OpenAlex, whole career)
Institution's track record	1 / 3	The University of Western Australia: institution h-index 1,026 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 6 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40887393)
Free to read	2 / 2	Free to read
Total	38 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is

Also tagged “examination”

840 studies in the library carry the topic tag “examination”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Similar studies

More on How common it is

See all studies in How common it is →